EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 36 (Octobre 2020) Hors série n° 1 Med Sci (Paris), 36 (2020) 50-55 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 36, Octobre 2020
Les jeunes contre le cancer : la Ligue en soutien
Page(s) 50 - 55
DOI https://doi.org/10.1051/medsci/2020195
Publié en ligne 14 octobre 2020
  1. Demaria O, Cornen S, Daeron M, et al. Harnessing innate immunity in cancer therapy. Nature 2019 ; 574 : 45–56. [PubMed] [Google Scholar]
  2. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016 ; 375 : 819–829. [Google Scholar]
  3. Chockley PJ, Chen J, Chen G, et al. Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-pecific immunosurveillance in lung cancer. J Clin Invest 2018 ; 128 : 1384–1396. [CrossRef] [PubMed] [Google Scholar]
  4. Souza-Fonseca-Guimaraes F.. NK cell-based immunotherapies: awakening the innate anti-cancer response. Discov Med 2016 ; 21 : 197–203. [PubMed] [Google Scholar]
  5. Chretien AS, Devillier R, Fauriat C, et al. NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-CT in patients with AML. Oncoimmunology 2017 ; 6 : e1307491. [CrossRef] [PubMed] [Google Scholar]
  6. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014 ; 192 : 5451–5458. [CrossRef] [PubMed] [Google Scholar]
  7. Pilipow K, Roberto A, Roederer M, et al. IL15 and T-cell stemness in T-cell-based cancer immunotherapy. Cancer Res 2015 ; 75 : 5187–5193. [Google Scholar]
  8. Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 2018 ; 19 : 723–732. [PubMed] [Google Scholar]
  9. Gauthier L, Morel A, Anceriz N, et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell 2019; 177 : 1701–13e16. [CrossRef] [PubMed] [Google Scholar]
  10. Chabannon C, Mfarrej B, Guia S, et al. Manufacturing natural killer cells as medicinal products. Front Immunol 2016 ; 7 : 504. [CrossRef] [PubMed] [Google Scholar]
  11. Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 2018; 23 : 181–92e5. [Google Scholar]
  12. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 2020; 382 : 545–53. [Google Scholar]
  13. Burga RA, Yvon E, Chorvinsky E, et al. Engineering the TGFbeta receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma. Clin Cancer Res 2019 ; 25 : 4400–4412. [CrossRef] [PubMed] [Google Scholar]
  14. Castriconi R, Carrega P, Dondero A, et al. Molecular mechanisms directing migration and retention of natural killer cells in human tissues. Front Immunol 2018 ; 9 : 2324. [CrossRef] [PubMed] [Google Scholar]
  15. Cichocki F, Valamehr B, Bjordahl R, et al. GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity. Cancer Res 2017 ; 77 : 5664–5675. [Google Scholar]
  16. Lynn RC, Weber EW, Sotillo E, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 2019 ; 576 : 293–300. [PubMed] [Google Scholar]
  17. Judge SJ, Murphy WJ, Canter RJ. Characterizing the dysfunctional NK cell: assessing the clinical relevance of exhaustion, anergy, and senescence. Front Cell Infect Microbiol 2020; 10 : 49. [CrossRef] [PubMed] [Google Scholar]
  18. Marusina AI, Burgess SJ, Pathmanathan I, et al. Regulation of human DAP10 gene expression in NK and T cells by Ap-1 transcription factors. J Immunol 2008 ; 180 : 409–417. [CrossRef] [PubMed] [Google Scholar]
  19. Viel S, Marcais A, Guimaraes FS, et al. TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal 2016; 9 : ra19. [Google Scholar]
  20. Tang PM, Zhou S, Meng XM, et al. Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development. Nat Commun 2017 ; 8 : 14677. [CrossRef] [PubMed] [Google Scholar]
  21. Viant C, Fenis A, Chicanne G, et al. SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells. Nat Commun 2014 ; 5 : 5108. [CrossRef] [PubMed] [Google Scholar]
  22. Celis-Gutierrez J, Boyron M, Walzer T, et al. Dok1 and Dok2 proteins regulate natural killer cell development and function. EMBO J 2014 ; 33 : 1928–1940. [PubMed] [Google Scholar]
  23. Kim WS, Kim MJ, Kim DO, et al. Suppressor of cytokine signaling 2 negatively regulates NK cell differentiation by iinhibiting JAK2 activity. Sci Rep 2017 ; 7 : 46153. [CrossRef] [PubMed] [Google Scholar]
  24. Palmer DC, Guittard GC, Franco Z, et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med 2015 ; 212 : 2095–2113. [CrossRef] [PubMed] [Google Scholar]
  25. Guittard G, Dios-Esponera A, Palmer DC, et al. The Cish SH2 domain is essential for PLC-gamma1 regulation in TCR stimulated CD8+ T cells. Sci Rep 2018 ; 8 : 5336. [CrossRef] [PubMed] [Google Scholar]
  26. Delconte RB, Guittard G, Goh W, et al. NK Cell priming from endogenous homeostatic signals is modulated by CIS. Front Immunol 2020; 11 : 75. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.